Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

MODHEP · Systems biology of liver cancer: an integrative genomic-epigenomic approach

FP7Status: CLOSED1 January 201130 June 2016EU funding €11,936,899

Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplastic phases to overt cancer. Until now, no systematic effort has been undertaken to investigate these multiple layers of genome organization and function during cancer development. MODHEP aims at providing a 360° understanding of liver cancer, one of the most common types of tumors and, because of the homogeneity of the hepatic tissue, the most experimentally tractable one. The consortium brings together elite European scientists in the fields of genetics, chromatin regulation, genomics, liver cancer, computational and systems biology. This combination of skills will allow us to investigate and model at unprecedented resolution the chain of events leading from environmental perturbations and the occurrence of driver mutations to preneoplastic disease and cancer. Our experimental plan reflects some grounded assumptions: 1. cancer cannot be modeled without detailed information on the preneoplastic stages of disease; 2. genetic heterogeneity in humans would make systems-level modeling non realistic from a practical point of view. Both of these limitations are bypassed by the use of well-defined mouse models, followed by evaluation of the main conclusions in clinical samples; 3. many early stage driving events in cancer represent epigenetic alterations, which are invisible to classical genetic analysis, and are confounded by secondary and tertiary events in established tumors. Our approach will enable the identification of therapeutically relevant early-stage genetic and epigenetic alterations and the definition of their interplay in tumor development and maintenance.

Consortium · 18 organisations

coordinator

FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA

IT · €687,842

participant

MATER MEDICAL RESEARCH INSTITUTE LIMITED

AU · €577,570

participant

INSTITUT PASTEUR

FR · €800,000

participant

FONDAZIONE TELETHON ETS

IT · €825,231

participant

ISTITUTO EUROPEO DI ONCOLOGIA SRL

IT · €1,762,573

participant

ABGI FRANCE

FR · €295,570

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €760,004

participant

RIKEN THE INSTITUTE OF PHYSICAL ANDCHEMICAL RESEARCH

JP · €951,000

participant

KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW

NL · €805,000

participant

WEIZMANN INSTITUTE OF SCIENCE

IL · €647,999

participant

BIOBYTE SOLUTIONS GMBH

DE · €318,600

participant

THE BABRAHAM INSTITUTE

UK · €797,486

participant

INSTITUT CURIE

FR · €1,362,500

participant

MEDICAL RESEARCH COUNCIL

UK · €11,904

participant

THE UNIVERSITY OF EDINBURGH

UK · €493,177

participant

NOVAMEN SAS

FR · €167,210

participant

FONDAZIONE SANTA LUCIA

IT · €574,148

participant

KING'S COLLEGE LONDON

UK · €99,085

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.